Trial Profile

Effects of Ivabradine on Neopterin and NT-Pro BNP in Patients With Congestive Heart Failure

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivabradine (Primary)
Indications Chronic heart failure
Focus Pharmacodynamics

Most Recent Events

03 Mar 2022 Primary endpoint (Neopterin) has been met according to the results published in the European Journal of Clinical Pharmacology
03 Mar 2022 Primary endpoint (NT-Pro BNP) has been met according to the results published in the European Journal of Clinical Pharmacology
03 Mar 2022 Results assessing short-term effect of ivabradine on NT-Pro BNP and neopterin in heart failure patients and assess the association between HR and these biomarkers published in the European Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com